Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05097638
Other study ID # 5884
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 20, 2018
Est. completion date February 4, 2020

Study information

Verified date October 2021
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Some of pulmonary tuberculous patients who completed their medication course experience lung function impairment


Description:

Some of pulmonary tuberculous patients who completed their medication course experience lung function impairment which may influence their quality of life. However, the pattern and nature of post-tuberculosis lung impairment is still not identified. Thus, the aim of this study was to determine the type and degree of lung physiology changes in previously treated tuberculous patients which latter may affect their quality of life; thus helping clinicians for early diagnosis of lung impairment, especially in tuberculous endemic areas.


Recruitment information / eligibility

Status Completed
Enrollment 210
Est. completion date February 4, 2020
Est. primary completion date November 1, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patient completed an outpatient course of standard first line anti-tuberculosis therapy and declared as cured Exclusion Criteria: - Smoker (to avoid spirometry biases). - Extrapulmonary tuberculosis cases - Multidrug resistant tuberculosis - known contraindications to spirometry testing - Individuals with chest wall deformities or neuromuscular diseases - Patients who failed to achieve acceptability and reproducibility criteria of the spirometry test - Defaulter cases or irregular treatment, - known coexisting chronic lung disease as history of asthma or interstitial lung diseases - A history of illicit drug use - Patients with comorbidities: renal and hepatic insufficiency, heart diseases and metabolic disorders.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
spirometry
Patient do spirometry

Locations

Country Name City State
Egypt Chest Department-faculty of medicine-Assuit university Assuit

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post tuberculosis lung functional impairment spirometry abnormality either: restrictive, obstructive, or mixed 6 months
Primary post tuberculosis persistent clinical symptoms either cough , sputum , breathlessness, hemoptysis 6 months
Primary Grading of obstruction function: grading according to GOLD : mild , moderate , severe , very severe 6 months
See also
  Status Clinical Trial Phase
Completed NCT04085133 - Prevalence and Burden of Bronchiectasis in Tuberculous Patients
Recruiting NCT05017324 - Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial N/A
Completed NCT04207112 - Economic Evaluation of New MDR TB Regimens Phase 2/Phase 3
Completed NCT04044001 - BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA) Phase 1/Phase 2
Withdrawn NCT03159975 - Safety and Immunogenicity Study of GX-70 in TB Patient Phase 1
Completed NCT02984579 - Line Probe Assay Evaluation Study N/A
Completed NCT05568368 - Time-to-Detection in Culture of Mycobacterium Tuberculosis
Recruiting NCT04930978 - Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
Not yet recruiting NCT05477966 - A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress
Active, not recruiting NCT05045391 - Pulmonary Aspergillosis in Tuberculosis Patients
Completed NCT02754765 - Evaluating Newly Approved Drugs for Multidrug-resistant TB Phase 3
Active, not recruiting NCT03896685 - Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) Phase 3